September 18, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Riyadh Gets a Summit Date Before the Gulf Trade Text Is WrittenMontenegro Has Fifteen Chapters and Six Months Left to Close ThemPyongyang Earns European Salaries Through Staff Nobody Ever MetNew Zealand Is the Partner Europe Talks To but Has Not SignedIndonesia Wants an October Signature Europe Has Not ScheduledNine Parliaments Still Stand Between Hanoi and Its Investment PactMEPs Back a Democracy Shield That Still Lacks a Legal ActWhy Due Cause Rarely Saves a Political Parody in CourtErasmus Budget Heads for an October Vote With Its Shares UnsettledEurope’s Pharma Package Waits on One Final Parliament Vote in AutumnCouncil Must Sign Off Five Defence Projects Before EDIP Pays OutInvestors Bid 152 Billion for 11 Billion of EU-BondsEgypt’s Macro-Financial Assistance Nears Its Most Political PaymentGreen Hydrogen Gets Fifty-Eight Million of a Twelve-Billion PledgeFerronickel Supply Puts a Chinese Mining Deal in DoubtEU Solidarity Fund Sends 489 Million After Winter StormsForeign Money Now Faces One Screening Rulebook Across the UnionFinland Entered the Deficit List While Nine Older Cases WaitMember States Must Now Criminalise the Abuse of Public OfficePaperless Trade Is the Part of the Singapore Deal That BitesRiyadh Gets a Summit Date Before the Gulf Trade Text Is WrittenMontenegro Has Fifteen Chapters and Six Months Left to Close ThemPyongyang Earns European Salaries Through Staff Nobody Ever MetNew Zealand Is the Partner Europe Talks To but Has Not SignedIndonesia Wants an October Signature Europe Has Not ScheduledNine Parliaments Still Stand Between Hanoi and Its Investment PactMEPs Back a Democracy Shield That Still Lacks a Legal ActWhy Due Cause Rarely Saves a Political Parody in CourtErasmus Budget Heads for an October Vote With Its Shares UnsettledEurope’s Pharma Package Waits on One Final Parliament Vote in AutumnCouncil Must Sign Off Five Defence Projects Before EDIP Pays OutInvestors Bid 152 Billion for 11 Billion of EU-BondsEgypt’s Macro-Financial Assistance Nears Its Most Political PaymentGreen Hydrogen Gets Fifty-Eight Million of a Twelve-Billion PledgeFerronickel Supply Puts a Chinese Mining Deal in DoubtEU Solidarity Fund Sends 489 Million After Winter StormsForeign Money Now Faces One Screening Rulebook Across the UnionFinland Entered the Deficit List While Nine Older Cases WaitMember States Must Now Criminalise the Abuse of Public OfficePaperless Trade Is the Part of the Singapore Deal That Bites
September 18, 2026

Newsletter

The European Post

Policy • Diplomacy • strategic insight

LATEST
Riyadh Gets a Summit Date Before the Gulf Trade Text Is WrittenMontenegro Has Fifteen Chapters and Six Months Left to Close ThemPyongyang Earns European Salaries Through Staff Nobody Ever MetNew Zealand Is the Partner Europe Talks To but Has Not SignedIndonesia Wants an October Signature Europe Has Not ScheduledNine Parliaments Still Stand Between Hanoi and Its Investment PactMEPs Back a Democracy Shield That Still Lacks a Legal ActWhy Due Cause Rarely Saves a Political Parody in CourtErasmus Budget Heads for an October Vote With Its Shares UnsettledEurope’s Pharma Package Waits on One Final Parliament Vote in AutumnCouncil Must Sign Off Five Defence Projects Before EDIP Pays OutInvestors Bid 152 Billion for 11 Billion of EU-BondsEgypt’s Macro-Financial Assistance Nears Its Most Political PaymentGreen Hydrogen Gets Fifty-Eight Million of a Twelve-Billion PledgeFerronickel Supply Puts a Chinese Mining Deal in DoubtEU Solidarity Fund Sends 489 Million After Winter StormsForeign Money Now Faces One Screening Rulebook Across the UnionFinland Entered the Deficit List While Nine Older Cases WaitMember States Must Now Criminalise the Abuse of Public OfficePaperless Trade Is the Part of the Singapore Deal That BitesRiyadh Gets a Summit Date Before the Gulf Trade Text Is WrittenMontenegro Has Fifteen Chapters and Six Months Left to Close ThemPyongyang Earns European Salaries Through Staff Nobody Ever MetNew Zealand Is the Partner Europe Talks To but Has Not SignedIndonesia Wants an October Signature Europe Has Not ScheduledNine Parliaments Still Stand Between Hanoi and Its Investment PactMEPs Back a Democracy Shield That Still Lacks a Legal ActWhy Due Cause Rarely Saves a Political Parody in CourtErasmus Budget Heads for an October Vote With Its Shares UnsettledEurope’s Pharma Package Waits on One Final Parliament Vote in AutumnCouncil Must Sign Off Five Defence Projects Before EDIP Pays OutInvestors Bid 152 Billion for 11 Billion of EU-BondsEgypt’s Macro-Financial Assistance Nears Its Most Political PaymentGreen Hydrogen Gets Fifty-Eight Million of a Twelve-Billion PledgeFerronickel Supply Puts a Chinese Mining Deal in DoubtEU Solidarity Fund Sends 489 Million After Winter StormsForeign Money Now Faces One Screening Rulebook Across the UnionFinland Entered the Deficit List While Nine Older Cases WaitMember States Must Now Criminalise the Abuse of Public OfficePaperless Trade Is the Part of the Singapore Deal That Bites

Europe’s Pharma Package Waits on One Final Parliament Vote in Autumn

Rudolf Nureyev
Parliament Reporter, Health and Wellbeing

Uppsala: Europe’s pharma package, the first full rewrite of EU medicines law since 2004, now needs one plenary vote in the European Parliament before it reaches the Official Journal, and MEPs are expected to take it this autumn. Researchers in this Swedish university city, where much of the continent’s antimicrobial resistance work sits, are watching a single clause more closely than the rest.

That clause creates a transferable exclusivity voucher. A company that develops a priority antibiotic earns one extra year of market protection, which it may apply to any product in its portfolio or sell to another firm. The pharma package pairs the reward with a blockbuster clause: no voucher may be used on a medicine whose gross annual sales topped €490 million in the preceding four years.

Sophie Løhde, Danish Minister for the Interior and for Health, closed the negotiation for the Council presidency in December and framed the bargain in industrial terms.

We are strengthening incentives for priority antibiotics, reducing red tape for the life science industry, and safeguarding the availability of essential medicines. — Sophie Løhde, Danish Minister for the Interior and for Health

The core exclusivity arithmetic changed less than industry feared and more than generic makers wanted. Under the agreement struck on 11 December 2025, a new medicine receives eight years of regulatory data protection and one year of market protection, extendable by a further year for innovative products meeting two of three conditions. Orphan medicines addressing an unmet need can reach eleven years in total.

Three other provisions carry real operational weight:

  • Article 56a lets member states oblige companies holding regulatory protection to supply medicines in quantities that meet patient need, with safeguards against parallel trade
  • the Bolar exemption now covers submissions for procurement tenders, so generics can be ready on day one after rights expire
  • manufacturers must notify shortages faster, publish prevention plans and act on medicines the EU lists as critical

The Parliament’s public health committee approved the compromise on 18 March 2026, eleven days after the Council published the consolidated texts. Since then the file has waited, which is unusual for a reform this size and reflects a plenary calendar crowded by the next long-term budget rather than any reopened dispute.

National health ministries have already started the arithmetic that follows adoption. Pricing authorities in smaller markets read Article 56a as leverage they have never held before, because a company that wants protection in the single market can no longer decline to launch in a state it considers unprofitable. Industry associations read the same article as a supply mandate without a price guarantee, and have said so throughout.

The reform also reshapes the European Medicines Agency. The agency’s own reform pages describe a leaner committee structure, shorter assessment timelines and patient representatives seated on the main scientific committee. Environmental risk assessment becomes a condition of market entry, a change driven by evidence that antimicrobial residues in water and soil feed resistance.

Whether the antibiotic voucher works is genuinely contested. Health economists have argued for years that a transferable reward overpays, because the year of protection is worth whatever the recipient’s best-selling product happens to earn, not what the antibiotic cost to develop. The blockbuster clause caps that transfer, and the Council insisted on it for exactly that reason. Supporters counter that no other instrument has moved a large manufacturer back into antibiotic discovery, a field most abandoned two decades ago.

Patient groups have a narrower worry. Shortages of older, cheap medicines drove much of the political energy behind this reform, and none of the new incentives touch the economics of generic production. The Council’s own explainer concedes that access still varies sharply across member states, with treatments unaffordable or simply unavailable in parts of the Union.

After the plenary vote and formal Council endorsement, the rules enter into force on publication, with long transition periods before most obligations bite. Companies planning launches in 2028 and beyond are already building schedules around the eight-plus-one regime, which means the vote confirms a framework the sector has priced in for months.

Comments